Similarities between Index of oncology articles and Semaxanib
Index of oncology articles and Semaxanib have 6 things in common (in Unionpedia): Angiogenesis inhibitor, Clinical trial, Colorectal cancer, Sunitinib, Tyrosine-kinase inhibitor, Vascular endothelial growth factor.
Angiogenesis inhibitor
An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis).
Angiogenesis inhibitor and Index of oncology articles · Angiogenesis inhibitor and Semaxanib ·
Clinical trial
Clinical trials are experiments or observations done in clinical research.
Clinical trial and Index of oncology articles · Clinical trial and Semaxanib ·
Colorectal cancer
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine).
Colorectal cancer and Index of oncology articles · Colorectal cancer and Semaxanib ·
Sunitinib
Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006.
Index of oncology articles and Sunitinib · Semaxanib and Sunitinib ·
Tyrosine-kinase inhibitor
A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases.
Index of oncology articles and Tyrosine-kinase inhibitor · Semaxanib and Tyrosine-kinase inhibitor ·
Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF), is a signal protein produced by cells that stimulates the formation of blood vessels.
Index of oncology articles and Vascular endothelial growth factor · Semaxanib and Vascular endothelial growth factor ·
The list above answers the following questions
- What Index of oncology articles and Semaxanib have in common
- What are the similarities between Index of oncology articles and Semaxanib
Index of oncology articles and Semaxanib Comparison
Index of oncology articles has 1711 relations, while Semaxanib has 16. As they have in common 6, the Jaccard index is 0.35% = 6 / (1711 + 16).
References
This article shows the relationship between Index of oncology articles and Semaxanib. To access each article from which the information was extracted, please visit: